ArticleMacromolecular bioscience2025
Development of a Decellularized Urinary Bladder Matrix and Heparin-Based Cryogel for Promoting Angiogenesis.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Decellularized Urinary Bladder Matrix and Heparin-Based Cryogel for Promoting Angiogenesis.Macromolecular bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Decellularized extracellular matrix(dECM)-based scaffolds have demonstrated potential in promoting cellular migration and tissue regeneration. In this study, dECM-based cryogel scaffolds are developed with sustained vascular endothelial growth factor (VEGF) release properties to enhance angiogenesis in ischemic tissues. VEGF plays a critical role in angiogenesis by stimulating cell proliferation and migration, but its therapeutic delivery remains challenging due to the need for precise dosing to avoid adverse effects. Cryogels, with their microporous structure, elasticity, and shape-recovery characteristics, offer an ideal platform for controlled VEGF delivery. Using decellularized porcine urinary bladder matrix extracellular matrix (dECM) and heparin, a VEGF-releasing cryogel scaffold is fabricated. The resulting dECM/heparin cryogel is a biocompatible scaffold capable of binding VEGF and releasing it over an extended period. This platform demonstrates significant angiogenic potential both in vitro and in a murine hindlimb ischemia model, highlighting its promise for therapeutic applications in tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.